Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CETP | P11597 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698616 | 0.92 | TSHR (0.48) | ALDH1A1TSHRL3MBTL1MAPK1TDP1 | |
| Hydrochloric Acid SCHEMBL7385052 | 0.90 | AGXT (0.46) | ALDH1A1TSHRL3MBTL1MAPK1TDP1 | |
| SCHEMBL15961256 | 0.90 | TSHR (0.46) | ALDH1A1TSHRL3MBTL1MAPK1TDP1 | |
| Butane SCHEMBL8010999 | 0.89 | PTGS1 (0.53) | ALDH1A1L3MBTL1KMT2ACYP2C19SLC6A2 | |
| SCHEMBL20589969 | 0.87 | ALDH1A1 (0.44) | ALDH1A1CETPTSHRL3MBTL1MAPK1 | |
| Ethylene Glycol SCHEMBL28921702 | 0.86 | TSHR (0.43) | ALDH1A1TSHRL3MBTL1MAPK1TDP1 | |
| Butane SCHEMBL8002745 | 0.85 | IDO1 (0.42) | ALDH1A1TSHRL3MBTL1CYP3A4TDP1 | |
| SCHEMBL29035063 | 0.85 | TSHR (0.41) | ALDH1A1TSHRL3MBTL1MAPK1TDP1 | |
| Butane SCHEMBL9066594 | 0.84 | TSHR (0.44) | ALDH1A1CETPTSHRL3MBTL1CYP3A4 | |
| Butane SCHEMBL3196642 | 0.83 | AGXT (0.44) | ALDH1A1MAPK1IDO1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111592487-A | Hydroximic acid group-containing diarylethene LSD1/HDACs double-target inhibitor, and preparation method and application thereof | 新乡医学院 | 2020-08-28 | — | — | CN | claimed |
| CN-107501169-A | A kind of trans diarylethene LSD1 inhibitor, its preparation method and application | 新乡医学院 | 2017-12-22 | — | — | CN | claimed |
| CN-107474011-A | A kind of the stibazole class LSD1 inhibitor of 2 phenyl 4, its preparation method and application | 新乡医学院 | 2017-12-15 | — | — | CN | claimed |
| CN-106045881-B | Resveratrol derivative, its preparation method and the application as LSD1 inhibitor | 新乡医学院 | 2017-10-31 | — | — | CN | claimed |
| CN-106045881-A | Resveratrol derivative, preparation method thereof and application of resveratrol derivative serving as LSD1 inhibitor | 新乡医学院 | 2016-10-26 | — | — | CN | claimed |
| US-9187621-B2 | Reflector for light-emitting devices | TICONA LLC (US) | 2015-11-17 | — | — | US | claimed |
| EP-2797996-A1 | REFLECTOR FOR LIGHT-EMITTING DEVICES | Ticona LLC (US) | 2014-11-05 | — | — | EP | claimed |
| US-20140299907-A1 | Reflector for Light-Emitting Devices | TICONA LLC (US) | 2014-10-09 | — | — | US | claimed |
| WO-2013101277-A1 | REFLECTOR FOR LIGHT-EMITTING DEVICES | TICONA LLC (US) | 2013-07-04 | — | — | WO | claimed |
| CN-100366605-C | Compounds to treat alzheimer's disease | ELAN PHARM INC (US) | 2008-02-06 | — | — | CN | claimed |
| US-20070004937-A1 | METHODS FOR THE PREPARATION OF PHOSPHONIC ACID DERIVATIVES | FERRO CORPORATION (US) | 2007-01-04 | — | — | US | claimed |
| CN-1447789-A | Compounds for treating alzheimer's disease | ELAN PHARM INC (US) | 2003-10-08 | — | — | CN | claimed |
| US-4100089-A | High-voltage insulating material comprising anti-tracking and erosion inhibiting compounds with insulating polymers | RAYCHEM CORPORATION (US) | 1978-07-11 | — | — | US | claimed |
| US-20240076305-A1 | Phosphonium Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2024-03-07 | — | — | US | disclosed |
| WO-2024015730-A2 | AMPHIPHILIC COMPOUNDS FOR ATTENUATING NEUROTOXICITY OF AMYLOID-BETA OLIGOMERS AND DIAGNOSTIC METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-3455282-B1 | POLYSILOXANE HYDRAULIC FLUIDS | COMMW SCIENT IND RES ORG (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-1052254-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND MEDICINE THEREOF | Eisai Co., Ltd. (JP) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000000490-A2 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| CN-87103809-A | The method for making of naphthane and indan derivative | — | 1987-12-02 | — | — | CN | disclosed |
| US-4223071-A | ANTITRACKING ADDITIVES, RESISTANCE TO HIGH VOLTAGE ERROSION | RAYCHEM CORPORATION (US) | 1980-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004937-A1 | METHODS FOR THE PREPARATION OF PHOSPHONIC ACID DERIVATIVES | PDXK, PPA1, P2RY6 | ALDH1A1 1180/4885CETP 4603/4885TSHR 2771/4885 |
| US-20240076305-A1 | Phosphonium Ion Channel Blockers and Methods for Use | TRPV1, TRPV5, TRPA1 | ALDH1A1 3411/4885CETP 3039/4885TSHR 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.